透過您的圖書館登入
IP:18.223.196.211
  • 期刊
  • OpenAccess

Clinical Outcomes of Systemic Lupus Erythematosus Patients on Peritoneal Dialysis: A Single-Center Experience in Taiwan

並列摘要


BACKGROUND: The aim was to evaluate the safety and rationale of peritoneal dialysis (PD) therapy in systemic lupus erythematous (SLE) patients with end-stage renal disease (ESRD). METHODS: Twenty-three SLE patients undergoing PD were compared with 46 age and gender matched non-diabetic PD patients. The demographic and biochemical data, lupus activities and infective complications were compared. RESULTS: The predialysis Charlson comorbidity index (CCI) were higher in SLE patients (3.8 ± 0.9 vs. 3.0 ± 1.2, P=0.001). Complement levels of C3, C4 and antibodies to dsDNA did not show signifi cant change before and after dialysis (P=0.71, 0.29, and 0.18, respectively). Although weekly dose of erythropoietin (EPO) used in SLE patients tended to be higher than that used in the control group (6913.0 ± 2539.0 vs. 5875.0 ± 1453.3), SLE patients had significantly lower hemoglobin level (8.5 ± 1.5 vs. 9.5 ± 1.4 g/ dL, P=0.008). The incidence of PD peritonitis was higher in SLE patients (0.81 vs. 0.79 episodes/100 patient-months, P < 0.001), while the incidence of non-catheter-related infections was lower in the SLE group (0.32 vs. 1.44 episodes/100 patient-months, P < 0.001). The technique and patient survival rate were comparable between groups (P=0.71 and P=0.93, respectively). CONCLUSION: Despite the higher incidence of PD-related peritonitis, higher predialysis CCI score and lower hemoglobin level in SLE patients compared with non-SLE patients, PD therapy is a safe initial renal replacement therapy with regard to patient and technique survival.

延伸閱讀